Better care for epidemics
Regina getting into PPE before going into the red zone (Sierra Leone, Port Loko , 2015 – Ebola treatment centre – GOAL). Photo credit: Rebecca Inglis
International Severe Acute Respiratory and emerging Infection Consortium
What we do
Our purpose is to prevent illness and deaths from infectious disease outbreaks.
We are a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases.
In December 2019, a novel coronavirus (SARS-CoV-2) emerged to cause a pandemic of a severe coronavirus disease (COVID-19). ISARIC has created tools for investigators to collect and store data in a standardised way and has supported clinical trials of treatments.
See below our featured research areas:
ISARIC provides a collaborative platform through which global, patient‐oriented clinical studies can be developed, executed and shared.
Protocols addressing the most important questions between and during epidemics of severe acute respiratory infections and other rapidly emerging public health threats are undertaken in order to generate new knowledge, maximise the availability of clinical information, and thereby save lives.
Healthcare professionals in COVID-19 hospital (Photo credit: Professor Bin Cao, China-Japan Friendship Hospital, China)
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
“These regional differences in mortality reflect differences in access to better health care that already existed before the pandemic”, explains Fernando Bozza, study coordinator and researcher at the National Institute of Infectious Disease.
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study
The QCOVID is a new risk prediction tool that uses readily available information about people, such as their age, ethnicity and whether they have certain comorbidities to help identify individuals at highest risk of developing severe illness.
“Genetic evidence is second only to clinical trials as a way to tell which treatments will be effective in a disease.”
Event date - 17/12/2020
This forum aims to review evidence and strategies for Non-invasive ventilation (NIV) in COVID, develop and promote research ideas and evidence-based practice.
Event date - 09/12/2020
Currently very little is known about the clinical, biological, psychological and socio-environmental impact of Coronavirus Disease 2019 (COVID-19). While most people have uncomplicated recoveries, some continue to live with prolonged illness and symptoms.
Event date - 26/11/2020
ISARIC partners have been at the forefront of clinical trials of COVID-19 treatments since the start of the pandemic. Recognising how hard it is to keep up with the extraordinary pace of COVID science, ISARIC will run a series of ‘Evidence Fora’ on COVID-19 treatment.